Dr. Christine Brezden-Masley is a practicing Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital. She is the Medical Director of the Cancer Program at Sinai Health System. She obtained her PhD in Medical Biophysics at Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto, an Associate Scientist at the Lunenfeld Tanenbaum Research Institute, and an Associate Scientist at the Li Ka Shing Knowledge Institute.  

She is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto Region. She treats both Breast and GI (colorectal and gastric cancers) malignancies and these are the major areas of her clinical research. Her main area of clinical research is cardiotoxicity from cancer therapy and has been the Co-Chair of the Annual Canadian Cardio-Oncology Network meeting, a collaborative national meeting improving cardiac heath in cancer patients. She is currently the President of the Canadian Cardio-Oncology Network and the Co-Chair of the 2020 Global Cardio-Oncology Summit.

[Contact Dr. Christine Brezden-Masley, MD, PhD, FRCPC]

Dr. Susan Dent is a Professor of Medicine, Associate Director of Breast Cancer Research and Co-Director of Cardio-Oncology at Duke University. She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the Canadian Cancer Trials Group.  

Her areas of research interest include breast cancer, and treatment related toxicities with a particular interest in cardiotoxicity. She is the Founder and past-president of the Cardiac Oncology Network, an organization dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity.

[Contact Dr. Susan Dent, MD, FRCPC]

Margot Davis is a cardiologist at Vancouver General Hospital and St. Paul’s Hospital, a Clinical Assistant Professor at the University of British Columbia, and Director of the UBC Cardiology-Oncology Program. She obtained her Bachelor of Science in Physiology at McGill University before attending medical school at the University of British Columbia.

She stayed at UBC for her Internal Medicine residency and Cardiology fellowship. She then completed fellowships in Advanced Heart Failure & Transplant Cardiology and Cardio-Oncology & Cardiac Amyloidosis at Stanford University School of Medicine. She is a candidate for a Masters of Science in clinical epidemiology at the Harvard School of Public Health. Her research interests are focused on the prevention, diagnosis, and management of heart disease related to cancer therapy and the epidemiology of heart disease in cancer survivors. She also has interests in cardiac amyloidosis and advanced heart failure.

Dr. Christine Simmons is a Medical Oncologist at the BCCA Vancouver and Clinical Associate Professor in the Department of Medicine at the University of British Columbia. She completed her residency training in Toronto, and completed a fellowship at Princess Margaret Hospital in Toronto. She also completed a Master’s in Clinical Epidemiology at University of Toronto. She is currently the Chair of Sarcoma Systemic Program for BCCA. 

She is the former chair of the Locally Advanced Breast Cancer National Consensus group and still plays a key role in that organisation. Her academic interests span both teaching and research, and she has held several leadership roles in the Undergraduate Medical Program at UBC in the areas of clinical skills and oncology education. Her research interests are in the areas of health services research in breast cancer and sarcoma. She recently founded the Sarcoma Outcomes Unit at the BC Cancer Agency, and is Founder and Chair of the not‑for‑profit organisation, Women in Cancer.

Dr. Paaladinesh Thavendiranathan MD, MSc SM, FRCPC, FASE is a cardiologist at the Toronto General Hospital, University of Toronto. He is an assistant professor of medicine and a clinician investigator.  His training was in advanced cardiovascular imaging and his current clinical practice involves work with cardiac MRI, CT, and echocardiography.

He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention which focuses on cardiac toxicity from systemic therapies including cancer therapy. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity.

Dr. Negar Mousavi is an assistant professor of medicine at McGill University. Her advanced training was in multi-modality cardiovascular imaging including echocardiography, cardiac MRI, cardiac CT and nuclear cardiology. She is the director of the Cardio-Oncology program at McGill University Health Center. Her research interest is in the utility of advanced imaging techniques for detection of subclinical cancer-therapy related micro- and macrovascular disease.

Dr. Ian Paterson is a Professor of Medicine in the Division of Cardiology at the University of Alberta. He completed his Cardiology training and an Echocardiography Fellowship at the McGill University, followed by a Cardiovascular MRI Fellowship at the National Institutes of Health. He is the Academic and Research Director of Cardiovascular Magnetic Resonance at the University of Alberta and Past President of the Canadian Society of Cardiovascular Magnetic Resonance. 

His research interests include: prevention and treatment of chemotherapy related cardiotoxicity; advanced cardiac imaging (MRI and echo); heart failure; and medical education.

Dr. Betty is a Professional Educationalist retired from OVC, University of Guelph where she assisted faculty to plan, apply and evaluate the transition from a traditional lecture-based medical model (Sage on the Stage) to an interactive, case-based veterinary medical model (Guide on the Side) of learning and clinical evaluation. Dr. Power has over forty years experience in Education and Administration in Nursing, Medicine, Veterinary Medicine, Health Record Administration and Dental Hygiene. 

Dr. Betty is an active volunteer in Health Science Education (Special Olympics, Can Breast Ca Foundation, Research Ethics Board U of Guelph) and an advocate for funding and prescribing Perjeta (Roche) in Breast Cancer HER-2 disease in progression. Dr. Power currently is a member of the Patient Advisory Board, St. Michael’s Hospital.